Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD33 CAR T-Cell Therapy for Relapsed/Refractory AML
NCT05672147Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2023
- Primary completion
- Sep 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD33 CAR-T cells in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Measurable Residual Disease up to 15 years and Dose-Limiting Toxicities up to 1 year. Started Dec 2023; status: recruiting.
02
Drugs
anti-CD33 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05672147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672147.